EP4259138A4 - Procédés de traitement d'affections cardiaques à l'aide de formes modifiées de trimétazidine - Google Patents
Procédés de traitement d'affections cardiaques à l'aide de formes modifiées de trimétazidine Download PDFInfo
- Publication number
- EP4259138A4 EP4259138A4 EP21904143.1A EP21904143A EP4259138A4 EP 4259138 A4 EP4259138 A4 EP 4259138A4 EP 21904143 A EP21904143 A EP 21904143A EP 4259138 A4 EP4259138 A4 EP 4259138A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- trimetazidine
- methods
- heart disease
- modified forms
- treating heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063123715P | 2020-12-10 | 2020-12-10 | |
| US202063123728P | 2020-12-10 | 2020-12-10 | |
| US202063123721P | 2020-12-10 | 2020-12-10 | |
| US202063123711P | 2020-12-10 | 2020-12-10 | |
| PCT/US2021/061583 WO2022125370A1 (fr) | 2020-12-10 | 2021-12-02 | Procédés de traitement d'affections cardiaques à l'aide de formes modifiées de trimétazidine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4259138A1 EP4259138A1 (fr) | 2023-10-18 |
| EP4259138A4 true EP4259138A4 (fr) | 2024-11-06 |
Family
ID=82932763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21904143.1A Pending EP4259138A4 (fr) | 2020-12-10 | 2021-12-02 | Procédés de traitement d'affections cardiaques à l'aide de formes modifiées de trimétazidine |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4259138A4 (fr) |
| WO (1) | WO2022125370A1 (fr) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020243120A1 (fr) * | 2019-05-31 | 2020-12-03 | Imbria Pharmaceuticals, Inc. | Méthodes de traitement de la fibrose faisant appel à des composés favorisant l'oxydation du glucose |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107530337B (zh) * | 2014-12-22 | 2021-07-09 | 贝克心脏与糖尿病研究所 | 治疗方法 |
| EP3419666A4 (fr) * | 2016-02-26 | 2019-10-09 | The Regents of The University of California | Thérapie par agonistes des récepteurs alpha-1-adrénergiques |
| EP3866794B1 (fr) * | 2018-10-17 | 2024-12-04 | Imbria Pharmaceuticals, Inc. | Procédés de traitement de maladies rhumatismales à l'aide de composés à base de trimétazidine |
| US20220249463A1 (en) * | 2019-05-31 | 2022-08-11 | Imbria Pharmaceuticals, Inc. | Methods of altering cardiac remodeling using compounds that promote glucose oxidation |
| US20220226313A1 (en) * | 2019-06-03 | 2022-07-21 | Imbria Pharmaceuticals, Inc. | Combination therapies that include an agent that promotes glucose oxidation and an inhibitor of pyruvate dehydrogenase kinase |
-
2021
- 2021-12-02 EP EP21904143.1A patent/EP4259138A4/fr active Pending
- 2021-12-02 WO PCT/US2021/061583 patent/WO2022125370A1/fr unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020243120A1 (fr) * | 2019-05-31 | 2020-12-03 | Imbria Pharmaceuticals, Inc. | Méthodes de traitement de la fibrose faisant appel à des composés favorisant l'oxydation du glucose |
Non-Patent Citations (4)
| Title |
|---|
| BERLINER DOMINIK ET AL: "The Treatment of Heart Failure with Reduced Ejection Fraction", DEUTSCHES ARZTEBLATT INTERNATIONAL FEB 2013, 22 May 2020 (2020-05-22), XP093206987, ISSN: 1866-0452, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643567/pdf/Dtsch_Arztebl_Int-117_0376.pdf> DOI: 10.3238/arztebl.2020.0376 * |
| KLONER ROBERT A. ET AL: "Stunned and Hibernating Myocardium: Where Are We Nearly 4 Decades Later?", JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 9, no. 3, 4 February 2020 (2020-02-04), XP093207112, ISSN: 2047-9980, Retrieved from the Internet <URL:https://www.ahajournals.org/doi/pdf/10.1161/JAHA.119.015502> DOI: 10.1161/JAHA.119.015502 * |
| MARON MARTIN S ET AL: "Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 67, no. 12, 21 March 2016 (2016-03-21), pages 1399 - 1409, XP029469187, ISSN: 0735-1097, DOI: 10.1016/J.JACC.2016.01.023 * |
| See also references of WO2022125370A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022125370A1 (fr) | 2022-06-16 |
| EP4259138A1 (fr) | 2023-10-18 |
| WO2022125370A8 (fr) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3697400A4 (fr) | Procédés d'utilisation d'inhibiteurs de l'ehmt2 dans le traitement ou la prévention de troubles du sang | |
| EP3745862A4 (fr) | Méthodes de traitement de pathologies fibrotiques | |
| EP3958869A4 (fr) | Compositions et procédés de traitement d'affections pulmonaires associées à un biofilm | |
| EP3932404A4 (fr) | Méthode de traitement d'une stéatose hépatique et/ou d'une stéatohépatite | |
| EP3565540A4 (fr) | Méthodes de traitement des maladies cardiovasculaires | |
| EP3752161A4 (fr) | Méthodes de traitement de la fibrose | |
| EP4248212A4 (fr) | Méthodes de traitement de maladies et troubles pulmonaires | |
| EP3664789A4 (fr) | Méthodes de traitement de maladies et de lésions des nerfs | |
| EP4168036A4 (fr) | Antagonistes de l'actrii-alk4 et méthodes de traitement de l'insuffisance cardiaque | |
| EP3746067A4 (fr) | Compositions et m& xc9;thodes de traitement d'un & x152;d& xc8;me pulmonaire ou d'une inflammation pulmonaire | |
| EP4313297A4 (fr) | Acides aminés lactoyle pour le traitement d'une maladie métabolique | |
| EP4232039A4 (fr) | Méthodes de traitement de cancers du poumon | |
| EP3826649A4 (fr) | Méthodes de traitement de troubles neurologiques | |
| EP4138900A4 (fr) | Méthode pour le traitement du cancer du col de l'utérus | |
| EP4301410A4 (fr) | Méthodes pour le traitement d'une maladie oculaire et thyroïdienne | |
| EP3833377A4 (fr) | Procédés de traitement de la neurofibromatose de type 1 et d'états apparentés avec une phosphatase alcaline | |
| EP4262814A4 (fr) | Méthodes de traitement de troubles associés à castor | |
| EP4229828A4 (fr) | Méthodes de traitement de la fibrose | |
| EP4125965A4 (fr) | Méthode de traitement d'une maladie pulmonaire avec un liquide amniotique acellulaire | |
| EP4259138A4 (fr) | Procédés de traitement d'affections cardiaques à l'aide de formes modifiées de trimétazidine | |
| EP4146273A4 (fr) | Procédés de traitement de la maladie de crohn au moyen d'un anticorps spécifique anti-il23 | |
| EP4003399A4 (fr) | Procédés de prévention ou de traitement de la dégénérescence graisseuse du muscle squelettique | |
| EP3914589A4 (fr) | Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl | |
| EP3840743A4 (fr) | Composés d'hygromycine a et procédés de traitement de maladies à spirochètes | |
| EP3914203A4 (fr) | Dispositifs de traitement de l'apnée obstructive du sommeil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230606 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20231221 |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20241008 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 295/088 20060101ALI20241001BHEP Ipc: A61K 31/497 20060101ALI20241001BHEP Ipc: C07D 213/80 20060101ALI20241001BHEP Ipc: C07D 401/12 20060101ALI20241001BHEP Ipc: C07D 241/04 20060101ALI20241001BHEP Ipc: C07D 241/02 20060101ALI20241001BHEP Ipc: A61P 9/00 20060101ALI20241001BHEP Ipc: A61K 31/496 20060101ALI20241001BHEP Ipc: A61K 31/495 20060101ALI20241001BHEP Ipc: A61K 31/455 20060101AFI20241001BHEP |